ライフサイエンスコーパス: pregnancy outcome

1 ssociated with female fertility, measured by pregnancy outcome.

2 factor burden after pregnancy regardless of pregnancy outcome.

3 in 71% of the women, with no relationship to pregnancy outcome.

4 this histiotrophic pathway leads to adverse pregnancy outcome.

5 res of EVT cells that can be correlated with pregnancy outcome.

6 evention of complications and improvement of pregnancy outcome.

7 new drug targets against associated adverse pregnancy outcome.

8 viral load through 1 year post-pregnancy by pregnancy outcome.

9 the maternal-fetal interface for successful pregnancy outcome.

10 presented differential coexpression based on pregnancy outcome.

11 ce could be used for blind categorization of pregnancy outcome.

12 rential coexpression (eFDR < 0.002) based on pregnancy outcome.

13 eral maternal infection, anemia, and adverse pregnancy outcomes.

14 ternal immune system, which may lead to poor pregnancy outcomes.

15 d in human placentas associated with adverse pregnancy outcomes.

16 tory responses that are associated with poor pregnancy outcomes.

17 e of the short, defined risk periods of most pregnancy outcomes.

18 ng plasma glucose (FPG) level and subsequent pregnancy outcomes.

19 ernal immune tolerance and adversely impacts pregnancy outcomes.

20 s on the association between HPV and adverse pregnancy outcomes.

21 IDO1 DNA methylation can adversely influence pregnancy outcomes.

22 otal of 1,005,568 (15.60%) women had adverse pregnancy outcomes.

23 sm whereby periodontitis can lead to adverse pregnancy outcomes.

24 ydrogen sulfide donors are likely to improve pregnancy outcomes.

25 associations between maternal phenotypes and pregnancy outcomes.

26 ain how Ct infection could result in adverse pregnancy outcomes.

27 armaceutical intervention to prevent adverse pregnancy outcomes.

28 diating maternal-fetal infection and adverse pregnancy outcomes.

29 The CLIP intervention did not reduce adverse pregnancy outcomes.

30 associated with adverse maternal or neonatal pregnancy outcomes.

31 bacteria, potentially giving rise to adverse pregnancy outcomes.

32 arch midwives throughout follow-up to assess pregnancy outcomes.

33 ciated malaria (PAM) is associated with poor pregnancy outcomes.

34 rs in general, increase the risk for adverse pregnancy outcomes.

35 lic adaptations are essential for successful pregnancy outcomes.

36 ulatory functions in female reproductive and pregnancy outcomes.

37 nducted to evaluate effects on fertility and pregnancy outcomes.

38 rticularly when active, can adversely affect pregnancy outcomes.

39 the first antenatal visit, and these improve pregnancy outcomes.

40 luding autoimmune diseases, malignancies and pregnancy outcomes.

41 low birthweight were the most common adverse pregnancy outcomes.

42 l syphilis infections caused 520 000 adverse pregnancy outcomes.

43 associated with an increased risk of adverse pregnancy outcomes.

44 placenta but was not previously analyzed in pregnancy outcomes.

45 (FGR) and pre-eclampsia are severe, adverse pregnancy outcomes.

46 they thought were most important to improve pregnancy outcomes.

47 in patients at an increased risk of adverse pregnancy outcomes.

48 attachment, leading to severely compromised pregnancy outcomes.

49 little is known about its ability to improve pregnancy outcomes.

50 -vitro studies, and studies without data for pregnancy outcomes.

51 meta-analysis to verify the effect of AH on pregnancy outcomes.

52 l weight gain is associated with unfavorable pregnancy outcomes.

53 een linked with an increased risk of adverse pregnancy outcomes.

54 on have shown mixed results and lack data on pregnancy outcomes.

55 ween the vaginal microbiome, host health and pregnancy outcomes.

56 rum parasitemia during pregnancy on multiple pregnancy outcomes.

57 d beneficial effects on metabolic status and pregnancy outcomes.

58 ever be associated with adverse maternal and pregnancy outcomes.

59 nts were conscious of its negative impact on pregnancy outcomes.

60 dvice with healthy eating advice on selected pregnancy outcomes.

61 dontal diseases are risk factors for adverse pregnancy outcomes.

62 iome may influence susceptibility to adverse pregnancy outcomes.

63 ss all three trimesters of pregnancy affects pregnancy outcomes.

64 phenol concentrations with reproduction and pregnancy outcomes.

65 These infections were associated with poor pregnancy outcomes.

66 ations were not associated with most adverse pregnancy outcomes.

67 ects of LGI dietary advice with HE advice on pregnancy outcomes.

68 vicular fluid (GCF) and serum cytokines, and pregnancy outcomes.

69 including letrozole, might result in better pregnancy outcomes.

70 contraindicated, could substantially improve pregnancy outcomes.

71 and acquired TTP have assisted in excellent pregnancy outcomes.

72 betes and cardiovascular disease but adverse pregnancy outcomes.

73 ntal dysfunction, and, consequently, adverse pregnancy outcomes.

74 for in machine learning, may play a role in pregnancy outcomes.

75 associated with HIV acquisition and adverse pregnancy outcomes.

76 mon worldwide and is associated with adverse pregnancy outcomes.

77 ssed the association between HPV and adverse pregnancy outcomes.

78 D and for whom data were available regarding pregnancy outcomes.

79 disease activity seems to negatively affect pregnancy outcomes.

80 disease as a risk factor for various adverse pregnancy outcomes.

81 and treatments increase the risk of adverse pregnancy outcomes.

82 rum in pregnancy is a major cause of adverse pregnancy outcomes.

83 ct of treatment for dental caries on adverse pregnancy outcomes.

84 maternal-fetal interface and prevent adverse pregnancy outcomes.

85 f resistance markers was not associated with pregnancy outcomes.

86 vascular diseases, malignancies, and adverse pregnancy outcomes.

87 tal disease, metabolic syndrome, and adverse pregnancy outcomes.

88 en linked to preterm birth and other adverse pregnancy outcomes.

89 countries lack, whilst potentially improving pregnancy outcomes.

90 ular disease, diabetes mellitus, and adverse pregnancy outcomes.

91 There were 151 women enrolled with known pregnancy outcomes; 69 (46%) reported IPT initiation dur

92 ived IPT were less likely to experience poor pregnancy outcomes (adjusted odds ratio [aOR], 0.83 [95%

93 pregnancy was not negatively associated with pregnancy outcomes after controlling for demographic, cl

94 pregnancy was not negatively associated with pregnancy outcomes after controlling for relevant demogr

95 Although reports of pregnancy outcomes after DOAC exposure are missing impor

96 Individual-level epidemiologic studies of pregnancy outcomes after maternal influenza are limited

97 mechanism for the recent increase in severe pregnancy outcomes after ZIKV infection in DENV-endemic

98 rvational prospective cohort study to assess pregnancy outcomes among HIV-positive women in Ukraine.

99 More data are needed on pregnancy outcomes among women conceiving on ART, partic

100 We assessed the impact of the acute event on pregnancy outcome and on neonatal complications, such as

101 he placenta is not a common cause of adverse pregnancy outcome and that the human placenta does not h

102 ernal syphilis increases the risk of adverse pregnancy outcomes and congenital syphilis, the subseque

103 Secondary end points included pregnancy outcomes and disease-free and overall survival

104 information on their FA supplementation and pregnancy outcomes and estimated each participant's expo

105 f pregnancy and its association with adverse pregnancy outcomes and examined the predictive accuracy.

106 Importantly, USPIO did not affect pregnancy outcomes and liver function in the mother and

107 assess the home visiting program's effect on pregnancy outcomes and maternal and child health through

108 omposition are often associated with adverse pregnancy outcomes and metabolic syndrome later in mater

109 nvestigate the relationships between adverse pregnancy outcomes and modifiable risk factors for cardi

110 d studies regarding the relationship between pregnancy outcomes and NMOSD disease activity.

111 Pregnancy outcomes and overall survival (OS) were second

112 e determined and tested for association with pregnancy outcomes and PAM indicators using linear and l

113 sed to assess the impact of PI-based cART on pregnancy outcomes and progesterone levels in vivo.

114 ssociation between dental caries and adverse pregnancy outcomes and the effect of treatment for denta

115 nks between maternal periodontal and adverse pregnancy outcomes and to promote oral health prophylaxi

116 rable to iron deficiency and related adverse pregnancy outcomes and, as such, are routinely recommend

117 epth of phenotypic information about adverse pregnancy outcomes, and clinical data and biospecimens f

118 cardiovascular diseases, overweight, eczema, pregnancy outcomes, and cognitive function.

119 sent in studies of occupational exposure and pregnancy outcomes, and many of them are easily addresse

120 e linked information on vaccination, adverse pregnancy outcomes, and potential confounders among wome

121 equestered parasites is associated with poor pregnancy outcomes, and protection may be mediated in pa

122 ndness, higher child mortality, anemia, poor pregnancy outcomes, and reduced work capacity.

123 s metabolic control, and a number of adverse pregnancy outcomes, and these associations are upheld in

124 osus (SLE) are at increased risk for adverse pregnancy outcome (APO).

125 Adverse pregnancy outcomes (APOs)-including pre-term birth, pre-

126 ring pregnancy and may contribute to adverse pregnancy outcomes (APOs).

127 Treatments to improve pregnancy outcomes are being studied.

128 Recruitment and pregnancy outcomes are complete but childhood follow-up

129 We assessed adverse pregnancy outcomes associated with ART initiated before

130 all individuals with HIV, few data exist for pregnancy outcomes associated with ART initiation before

131 haps be involved in the induction of adverse pregnancy outcomes associated with long-term consumption

132 was analysed in randomly assigned women with pregnancy outcomes at or after 20 weeks, according to a

133 mprove the ability to predict severe adverse pregnancy outcomes (AUC: 0.64; likelihood ratio: 2.32; P

134 plausibility of adaptively monitoring early pregnancy outcomes based on updating hCG measurements.

135 s of age with labor and delivery or abortive pregnancy outcome between 2005 and 2013.

136 fficiency lead to maternal and fetal adverse pregnancy outcome, but their pathologic mechanisms are u

137 as a crucial period for influencing not only pregnancy outcomes, but also future maternal and child h

138 toxins by intensified hemodialysis improves pregnancy outcomes, but small numbers and the absence of

139 ted low-dose aspirin might positively affect pregnancy outcomes, but this possibility has not been ad

140 med Fisher exact tests to compare subsequent pregnancy outcomes by randomized arm.

141 SPAZ may protect against adverse pregnancy outcomes by reducing inflammation and preventi

142 istance and the impact such selection has on pregnancy outcomes can guide future interventions.

143 xposed participants, 11 (16%) had an adverse pregnancy outcome compared to 23 of 82 (23%) IPT-unexpos

144 9 IPT-exposed women, 11 (16%) had an adverse pregnancy outcome compared with 23 (28%) IPT-unexposed w

145 unosuppression do not adversely affect their pregnancy outcomes compared with adult-tx mothers.

146 Pregnancy outcome data are inconsistently captured in ph

147 The time from the first (index) pregnancy outcome date to the next pregnancy was modeled

148 The time from the first (index) pregnancy outcome date to the next pregnancy was modelle

149 levated anticardiolipin levels may influence pregnancy outcomes due to interactions with annexin V.

150 are potentially at increased risk of adverse pregnancy outcomes, due to a range of factors, including

151 Reliable data are lacking on pregnancy outcomes during Ebola virus disease (EVD) epid

152 xiety/depression was associated with adverse pregnancy outcomes (e.g. preeclampsia, adjusted Odds Rat

153 dose response between dialysis intensity and pregnancy outcomes emerged, with live birth rates of 48%

154 regnant Women With Metabolic Risk Factors on Pregnancy Outcomes (ESTEEM) trial with similar trials us

155 maternal syphilis caused substantial adverse pregnancy outcomes, even in women receiving antenatal ca

156 association between IPT exposure and adverse pregnancy outcomes (fetal demise, prematurity, low birth

157 association between IPT exposure and adverse pregnancy outcomes (fetal demise, prematurity, low birth

158 nal, placental, and fetal viral infection to pregnancy outcome, fetal development, and maternal well-

159 egnancy can have devastating consequences on pregnancy outcomes, fetal development, and maternal heal

160 Pre-Pregnancy Checkups Project and completed pregnancy outcomes follow-up between 2010 and 2016 in Ch

161 There are very little data available on pregnancy outcomes following antenatal exposure to other

162 We analyzed pregnancy outcomes following recovery from TTP associate

163 Pregnancy outcomes for child-tx mothers are similar to t

164 Adverse pregnancy outcomes for women who conceive on antiretrovi

165 Pregnancy outcomes for women who received a kidney trans

166 The incidence of pregnancy outcomes for women with the purely obstetric f

167 We compared pregnancy outcomes from 22 pregnancies in the Toronto Pr

168 knowledge of CDC-accredited 25(OH)D data and pregnancy outcomes from a large, clinically validated, p

169 tion of safer conception methods and HIV and pregnancy outcomes from Sakh'umndeni, a novel safer conc

170 stage 1 CKD remained associated with adverse pregnancy outcomes (general combined outcome) in women w

171 for metabolic signature: (1) SLE and normal pregnancy outcome (Group 1, n = 21); (2) SLE with APO (G

172 efined by GDM [the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study] or were identified as ch

173 Periodontal disease and pregnancy outcomes have been claimed to be associated wi

174 Associations between vitamin D and pregnancy outcomes have been inconsistent.

175 anges such as impaired fertility and adverse pregnancy outcomes have been related to female asthma.

176 entails immune homeostasis loss and adverse pregnancy outcome in mice.

177 Pregnancy outcome in patients with ICP (N = 307) was stu

178 am the biochemical, obstetric management and pregnancy outcome in women with intrahepatic cholestasis

179 pectively investigated 27 maternal and fetal pregnancy outcomes in 14 women with aHUS from the Vienna

180 of inflammation and angiogenesis and adverse pregnancy outcomes in 2,012 Papua New Guinean women.

181 pregnancy have been associated with adverse pregnancy outcomes in a few studies but not in other stu

182 ion-level evidence of a reduction in adverse pregnancy outcomes in cohorts of women offered HPV vacci

183 udy were to investigate invasion and adverse pregnancy outcomes in gerbils orally exposed to L. monoc

184 r a Mediterranean-style diet reduces adverse pregnancy outcomes in high-risk women.

185 sium supplementation on metabolic status and pregnancy outcomes in magnesium-deficient pregnant women

186 sium supplementation on metabolic status and pregnancy outcomes in maternal-child dyads affected by g

187 kyl substance (PFAS) associated with adverse pregnancy outcomes in mice and humans, but little is kno

188 Statins have been linked to improved pregnancy outcomes in mouse models of PE and APS, possib

189 ime, metformin should not be used to improve pregnancy outcomes in obese women without diabetes.

190 denafil did not prolong pregnancy or improve pregnancy outcomes in severe early-onset fetal growth re

191 Pregnancy outcomes in SSRI users were compared with thos

192 x infections are important causes of adverse pregnancy outcomes in the Asia-Pacific region.

193 rsely affect successful conception and early pregnancy outcomes in the first and second trimester (<2

194 We describe challenges in studying adverse pregnancy outcomes in the setting of observational resea

195 individualised risk estimates for the early pregnancy outcomes in the short term.

196 around 2-4%, but little is known about other pregnancy outcomes in this setting.

197 Monitoring of pregnancy outcomes in Ukraine will be important as use o

198 Iron deficiency has negative effects on pregnancy outcomes in women and on immune function and n

199 Truven Health database, risk ratios for the pregnancy outcomes in women experiencing relapses versus

200 gested that progesterone therapy may improve pregnancy outcomes in women who have bleeding in early p

201 rombotic thrombocytopenic purpura (TTP), but pregnancy outcomes in women who have recovered from acqu

202 The incidence of pregnancy outcomes in women with constitutive thrombophi

203 ew studies have assessed the risk of adverse pregnancy outcomes in women with multiple sclerosis (MS)

204 We compared pregnancy outcomes in women with r-AKI without history o

205 study suggests that pravastatin may improve pregnancy outcomes in women with refractory obstetric AP

206 l syphilis infections caused 350 000 adverse pregnancy outcomes including 143 000 early fetal deaths

207 Pregnancy outcomes including live birth rates, gestation

208 were both at increased risk of many adverse pregnancy outcomes, including cesarean section and need

209 rnal hypertension is associated with adverse pregnancy outcomes, including fetal growth restriction (

210 gnificant between-group differences in other pregnancy outcomes, including pregnancy loss or preterm

211 This study compares pregnancy outcomes, including rates of stillbirth (fetal

212 The primary outcomes were adverse pregnancy outcomes, including spontaneous abortion, pret

213 ception IFG or DM had higher risk of adverse pregnancy outcomes, including spontaneous abortion, PTB,

214 MS and pregnancy outcomes (infections, cesarean delivery, prete

215 ts are known to increase the risk of adverse pregnancy outcomes interventions need to be sparing.

216 urther investigation of these differences in pregnancy outcomes is a public health priority.

217 S), we assessed whether the risk for adverse pregnancy outcomes is associated with CKD by comparing p

218 common during pregnancy but their impact on pregnancy outcomes is unclear.

219 f clinically recovered AKI (r-AKI) on future pregnancy outcomes is unknown.

220 educe the risk of ESKD in women with adverse pregnancy outcomes is worthy of further investigation.

221 Prediction, largely based on prior pregnancy outcomes, is not possible in women pregnant fo

222 sely, but given the low incidence of adverse pregnancy outcomes, large populations must be studied.

223 tions have also been associated with adverse pregnancy outcomes; limited data have suggested that the

224 and examined the effects of fetal growth on pregnancy outcomes, maternal BP, and glucose levels duri

225 s between antenatal IPT exposure and adverse pregnancy outcomes, maternal TB, all-cause mortality, an

226 Temperature-related effects on pregnancy outcomes merit additional investigation.

227 as not significantly associated with adverse pregnancy outcomes (miscarriage, stillbirth, preterm, sm

228 late oral inflammatory load (OIL) to adverse pregnancy outcomes more precisely, but given the low inc

229 ployed two high-quality databases with known pregnancy outcomes (n = 221).

230 ase (n = 10), diabetes (n = 12), and adverse pregnancy outcomes (n = 7).

231 pilepsy and antiepileptic drug exposure with pregnancy outcomes needs to be quantified to guide manag

232 Adverse pregnancy outcomes occurred only in the dams treated wit

233 and Cardiac disease (ROPAC), we describe the pregnancy outcome of 212 patients with an MHV.

234 hood ratio for a composite of severe adverse pregnancy outcomes of 25(OH)D concentrations <25 nmol/L

235 outcomes is associated with CKD by comparing pregnancy outcomes of 504 pregnancies in women with CKD

236 s prior to conception significantly affected pregnancy outcomes of female rats, with respect to deliv

237 This study examines the pregnancy outcomes of individuals infected with SARS-CoV

238 Pregnancy outcomes of perinatally human immunodeficiency

239 ing pregnancy, concerns about the effects on pregnancy outcome often arise.

240 MR was not associated with increased adverse pregnancy outcomes or augmented risk of malaria in the i

241 xt is unlikely to have additive benefits for pregnancy outcomes or child growth.

242 either trial in any other neurocognitive or pregnancy outcomes or in the incidence of adverse events

243 HbAC and HbAS were not associated with other pregnancy outcomes or PAM indicators.

244 e asked questions regarding family planning, pregnancy outcomes, parenthood, and gender issues in the

245 thalates has been linked to numerous adverse pregnancy outcomes, potentially through an oxidative str

246 The Pregnancy Outcome Prediction (POP) study was a prospecti

247 The Pregnancy Outcome Prediction (POP) study was a prospecti

248 cases of term FGR and 299 controls from the Pregnancy Outcome Prediction (POP) study, conducted in C

249 the effects of disease activity, we examined pregnancy outcomes (preterm birth, stillbirth, small for

250 vational studies and 397 pregnant women (399 pregnancy outcomes) purposely received ivermectin as par

251 re included, of whom 496 pregnant women (500 pregnancy outcomes) received ivermectin inadvertently du

252 nsecure pregnancy effect (women with adverse pregnancy outcomes reduce their exposures in subsequent

253 Treatment improves immediate pregnancy outcomes, reducing excess fetal growth and adi

254 Biomarkers for these adverse pregnancy outcomes remain elusive.

255 ever, its effects within the placenta and on pregnancy outcomes remain largely unknown.

256 As an adverse pregnancy outcome, small-for-gestational-age has been ex

257 f an event included in the composite adverse pregnancy outcome (stillbirth or spontaneous abortion, l

258 ' gestation in the Hyperglycemia and Adverse Pregnancy Outcome Study.

259 d Health and Human Development's Nulliparous Pregnancy Outcomes Study-Monitoring Mothers-to-Be (nuMoM

260 used data from 7572 women in the Nulliparous Pregnancy Outcomes Study: monitoring mothers-to-be.

261 f biomass fuels has been linked with adverse pregnancy outcomes such as low birth weight, stillbirth,

262 HG has been associated with adverse pregnancy outcomes such as low birth weight.

263 ernal-fetal dialogue could result in adverse pregnancy outcomes such as preterm birth.

264 ncentration has been associated with adverse pregnancy outcomes, such as gestational diabetes.

265 pathy (DV) has been shown to predict adverse pregnancy outcomes, such as preeclampsia, which can lead

266 uenza vaccination might also prevent adverse pregnancy outcomes, such as preterm birth.

267 od-borne pathogen that can result in adverse pregnancy outcomes, such as stillbirth or premature deli

268 n maternal anxiety or depression and adverse pregnancy outcomes, taking possible familial confounding

269 with a significantly higher risk of adverse pregnancy outcomes than no such exposure.

270 o immigrate to the United States have better pregnancy outcomes than their US-born counterparts.

271 during pregnancy is associated with adverse pregnancy outcomes that are known to be more prevalent i

272 cts in studies of occupational exposures and pregnancy outcomes: the healthy hire effect, the healthy

273 isease and mortality; however, when studying pregnancy outcomes, these effects might differ because o

274 h periodontitis, are associated with adverse pregnancy outcomes, thrombotic conditions, and accelerat

275 rtant implications for infection and adverse pregnancy outcomes throughout gestation and should be of

276 relative to total energy intake and adverse pregnancy outcomes using targeted maximum likelihood est

277 the vaginal microbiome and its influence on pregnancy outcome varies with pregnancy history.

278 The adjusted odds of having an adverse pregnancy outcome was 2.5 (95% confidence interval, 1.0-

279 The adjusted odds of having an adverse pregnancy outcome was 2.5 (95%CI: 1.0, 6.5; p=0.048) tim

280 Information on pregnancy outcome was available in 336 (55%) of 614 preg

281 A pregnancy outcome was recorded for 266 (96%) women with

282 dary autoimmunity, malignancy and death, and pregnancy outcomes was recorded.

283 ransport and treatment that underlie adverse pregnancy outcomes, we aimed to reduce all-cause adverse

284 ng IVF to investigate human reproduction and pregnancy outcomes, we found that concentrations of some

285 Associations between infection and pregnancy outcomes were assessed in case-control analyse

286 Pregnancy outcomes were assessed using logistic regressi

287 and endothelial function were assessed, and pregnancy outcomes were determined.

288 Some risk factors for adverse pregnancy outcomes were directly associated with HIV and

289 Laboratory test results and pregnancy outcomes were evaluated for a subgroup of preg

290 cts in infants and fetuses and other adverse pregnancy outcomes were identified among the women who h

291 environmental determinants of fertility and pregnancy outcomes were included.

292 very; however, their risks for other adverse pregnancy outcomes were not elevated.

293 Pregnancy outcomes were recorded at parturition.

294 Pregnancy outcomes were self-reported, and we estimated

295 ut has recently been associated with adverse pregnancy outcomes when initiated during pregnancy.

296 ut has recently been associated with adverse pregnancy outcomes when initiated during pregnancy.

297 s globally, monitoring for potential adverse pregnancy outcomes will be crucial.

298 recapitulates many features of human adverse pregnancy outcome, with pregnancies characterized by fet

299 Iron disorders are associated with adverse pregnancy outcomes, yet iron homeostatic mechanisms duri

300 Secondhand smoke can cause adverse pregnancy outcomes, yet there is a lack of effective smo